Revolution Medicines priced a $1.5 billion follow-on offering, following top-line Phase 3 results for its RAS inhibitor daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The transaction was structured as the company’s biggest public raise to date, with 10.56 million shares priced just days after the clinical data that boosted investor enthusiasm. The financing comes amid heightened market attention for RAS-targeted therapy, where daraxonrasib’s reported survival benefit set a high bar for subsequent regulatory and commercial discussions. Revolution’s move signals confidence in turning trial momentum into balance-sheet capacity for execution through the remaining regulatory pathway. Separately, Revolution’s offering is part of a broader re-acceleration in biotech capital markets, with investors increasingly rewarding late-stage catalysts. The timing also suggests management is leaning into liquidity to sustain development timelines and prepare for potential filing activity. For industry watchers, the scale of the raise underscores how Phase 3 readouts are again driving equity appetite—and how quickly public markets are re-engaging with oncology risk when datasets look durable.